Loading…
Aclaris Therapeutics, Inc. is projected to rise to $6.97 by 2027, a +25% move from its current price of $5.58. ACRS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $5.43 | $5.58 | $5.74 | +0.09% |
| Jul 14 | $5.38 | $5.59 | $5.81 | +0.17% |
| Jul 15 | $5.33 | $5.59 | $5.87 | +0.26% |
| Jul 16 | $5.30 | $5.60 | $5.92 | +0.35% |
| Jul 17 | $5.27 | $5.60 | $5.96 | +0.43% |
| Jul 18 | $5.24 | $5.61 | $6.00 | +0.52% |
| Jul 19 | $5.22 | $5.61 | $6.04 | +0.61% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.22 | $5.61 | $6.04 | +0.61% |
| Week 2 | $5.10 | $5.65 | $6.26 | +1.21% |
| Week 3 | $5.01 | $5.68 | $6.44 | +1.83% |
| Week 4 | $4.94 | $5.72 | $6.61 | +2.44% |
| Week 5 | $4.89 | $5.75 | $6.76 | +3.07% |
| Week 6 | $4.84 | $5.79 | $6.91 | +3.69% |
| Week 7 | $4.80 | $5.82 | $7.05 | +4.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. Its product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc.
was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS is the stock with current price $5.71 and market capitalization of $797.48M, ranking 2721. The current market position provides a baseline for evaluating the stock’s near-term risk and opportunity. The forecast suggests upside potential over the long run, with a 2026 average price of $5.71 and a path toward higher values, including a 2030 average of $13.87 and a 2050 average of $112.05 with a 2050 maximum of $208.54.
A major floor 45.5% below — a decisive break under it would weaken the trend.
The nearest floor, 26.5% below — buyers have tended to step in here.
Price is pressing into resistance (2.3% away) — a breakout level to watch.
A major ceiling 20.8% above — clearing it would confirm fresh momentum.
Key ACRS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACRS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.58 | Sell | $5.56 | Buy |
| MA 10 | $5.41 | Buy | $5.40 | Buy |
| MA 20 | $4.99 | Buy | $5.14 | Buy |
| MA 50 | $4.74 | Buy | $4.75 | Buy |
| MA 100 | $4.21 | Buy | $4.31 | Buy |
| MA 200 | $3.47 | Buy | $3.68 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.48 | Neutral |
| Stoch RSI (14) | 54.68 | Neutral |
| CCI (20) | 93.49 | Neutral |
| Williams %R (14) | -14.13 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 13.41 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 85.87 | Sell |
| TRIX (15) | 0.70 | Buy |
| Awesome (5,34) | 0.81 | Buy |
| Ultimate (7,14,28) | 68.77 | Neutral |
| Momentum (10) | 0.67 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 5.68 | Sell |
| ADX (14) | 25.77 | Buy |
| ATR (14) | 0.13 | Info |
The 30-day technical picture shows bullish sentiment in the near term with RSI (14) at 70 and a chart suggesting upside momentum. The 50-day simple moving average sits at $4.71 and the 200-day simple moving average at $3.45, indicating a positive trend compared with the price level. Support is at $4.10 and resistance at $5.71, framing the near-term trading band.
The 30-day trading range spans from $4.75 to $6.86, underscoring the recent volatility level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.62 | $5.58 | $7.66 | 0% | Neutral | |
| $5.55 | $6.97 | $9.27 | +25% | Bullish | |
| $6.29 | $8.12 | $11.21 | +46% | Bullish | |
| $8.20 | $10.85 | $15.41 | +94% | Bullish | |
| $10.05 | $13.57 | $19.76 | +143% | Bullish | |
| $11.61 | $15.98 | $23.76 | +186% | Bullish | |
| $13.14 | $18.39 | $27.88 | +230% | Bullish | |
| $14.03 | $19.96 | $30.79 | +258% | Bullish | |
| $14.92 | $21.57 | $33.80 | +287% | Bullish | |
| $16.24 | $23.82 | $37.88 | +327% | Bullish | |
| $27.14 | $42.59 | $72.06 | +663% | Bullish | |
| $63.32 | $111.60 | $206.64 | +19.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.62 | $5.58 | $6.67 | +0.00% |
| August 2026 | $4.87 | $5.74 | $6.96 | +2.95% |
| September 2026 | $5.08 | $6.04 | $7.40 | +5.09% |
| October 2026 | $5.10 | $6.10 | $7.55 | +1.13% |
| November 2026 | $4.99 | $6.00 | $7.48 | -1.69% |
| December 2026 | $5.05 | $6.10 | $7.66 | +1.66% |
Click any year to see its month-by-month ACRS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Aclaris Therapeutics, Inc.'s 2026 outlook centres on $5.58, within a $2.62 to $7.66 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ACRS could reach as high as $9.27, with a base case around $6.97 and support toward $5.55 — roughly +25% from $5.58. Buyers look set to stay in control over this stretch.
Expect ACRS to range from $6.29 to $11.21 through 2028. The $8.12 average target implies a +46% move from current prices. That is up +16% on the projected 2027 average. Momentum favours further upside here.
The ACRS price prediction for 2029 points to an average of $10.85 (low $8.20, high $15.41) — a potential gain of +94% on today's $5.58. Buyers look set to stay in control over this stretch.
In 2030, ACRS is projected to trade between $10.05 and $19.76, averaging $13.57 — a potential gain of +143% from today's $5.58. That is up +25% on the projected 2029 average. Momentum favours further upside here.
Aclaris Therapeutics, Inc.'s 2031 outlook centres on $15.98, within a $11.61 to $23.76 range. That is up +18% on the projected 2030 average. That marks a +186% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ACRS could reach as high as $27.88, with a base case around $18.39 and support toward $13.14 — roughly +230% from $5.58. Momentum favours further upside here.
Expect ACRS to range from $14.03 to $30.79 through 2033. The $19.96 average target implies a +258% move from current prices. That is up +9% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ACRS price prediction for 2034 points to an average of $21.57 (low $14.92, high $33.80) — a potential gain of +287% on today's $5.58. Momentum favours further upside here.
In 2035, ACRS is projected to trade between $16.24 and $37.88, averaging $23.82 — a potential gain of +327% from today's $5.58. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Aclaris Therapeutics, Inc.'s 2040 outlook centres on $42.59, within a $27.14 to $72.06 range. That is up +79% on the projected 2035 average. That marks a +663% change versus current levels. Momentum favours further upside here.
By 2050, ACRS could reach as high as $206.64, with a base case around $111.60 and support toward $63.32 — roughly +19.0x from $5.58. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACRS today (≈ 179.21147 ACRS) could be worth
$19,999.13
+$18,999.13 (+1900%) by 2050 · US Dollar
Based on the average projected ACRS price of $111.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACRSwould be worth at today's price.
$1,000 invested in ACRS on Jul 10, 2025 (≈ 628.930804 ACRS) would be worth
$3,509.43
+$2,509.43 (+250.9%) today · 3.51× · US Dollar
Based on a ACRS entry price of $1.59 vs. today's $5.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.56 | $1,003.6 | +0.4% |
| 1 month ago | $4.1 | $1,360.98 | +36.1% |
| 3 months ago | $4.04 | $1,381.19 | +38.1% |
| 6 months ago | $2.66 | $2,097.74 | +109.8% |
| 1 year ago | $1.59 | $3,509.43 | +250.9% |
| All time (5.0y) ago | $16.85 | $331.16 | -66.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACRS forecast.
Our base-case forecast reaches $11.00 around 2030.
Implied market cap at $11.00: $1.54B
Over the multi-year forecast, the path reflects growing value from a 2026 min of $2.62, avg $5.71, max $7.86 with neutral sentiment and 0% ROI, to a 2027 min $5.65, avg $7.11, max $9.47 with 24.5% ROI and bullish sentiment, and continuing higher through 2028 (avg $8.28, max $11.45, ROI 45%), 2029 (avg $11.18, max $15.92, ROI 95.8%), and 2030 (avg $13.87, max $20.24, ROI 142.9%). The forecast extends through 2031–2035 with continued bullish sentiment and rising average prices (2031 avg $16.19, 2032 $18.66, 2033 $20.11, 2034 $21.71, 2035 $24.25) and then accelerates toward the long horizon (2040 avg $42.70, max $72.56, ROI 647.9) and (2050 avg $112.05, max $208.54, ROI 1862.4). These are estimates and not guarantees, reflecting potential upside under favorable conditions but acknowledging uncertainty.
Tap a question to reveal the answer.
2030 min: $10.25, avg: $13.87, max: $20.24; ROI: 142.9%; sentiment: BULLISH.
The forecast shows Neutral sentiment in 2026 and Bullish sentiment from 2027 onward, with year-by-year upside and ROI figures ranging up to 1862.4% by 2050. These are estimates, not guarantees.
Yes. The 2050 forecast max is $208.54, and the 2050 average is $112.05, indicating a potential to exceed $100 under the projected path.
Current price: $5.71. Market cap: $797.48M.
30-day range: $4.75 to $6.86. Annualized volatility: 50%.
Aclaris Therapeutics, Inc. Community Discussion
0Share your Aclaris Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.